Phase II Study of High Dose Cyclophosphamide, Mitoxantrone, and Carboplatin With Autologous Bone Marrow Transplantation in Refractory or Relapsed Ovarian Carcinoma

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Diagnosis of refractory or relapsed ovarian epithelial cancer

- Must have failed prior regimen containing cisplatin or carboplatin

- Bidimensionally measurable or evaluable disease

- Serial CA-125 antigen titers or cytologically positive pleural effusion and/or
ascites acceptable as evaluable disease

- Autologous bone marrow harvest of greater than 1.2 x 10 to the eighth nucleated
cells/kg required before study entry

- No evidence of tumor at marrow harvest sites by bilateral bone marrow aspirates and
biopsies, pelvic x-ray, and bone scan

- CNS involvement allowed

PATIENT CHARACTERISTICS:

Age:

- Under 65

Performance status:

- SWOG 0-2

Life expectancy:

- At least 8 weeks

Hematopoietic:

- WBC greater than 3,500/mm^3

- Platelet count greater than 100,000/mm^3

- Hemoglobin greater than 10.0 g/dL

Hepatic:

- Bilirubin less than 2.0 mg/dL

- SGOT and SGPT less than 2 times upper limit of normal

Renal:

- Creatinine clearance greater than 60 mL/min

- No prior hemorrhagic cystitis

Cardiovascular:

- LVEF greater than 45% by MUGA scan

Other:

- No hearing loss in voice tones

- No active infection

- No psychological contraindication to study treatment

- Not pregnant

- Negative pregnancy test

- HIV negative

- General medical condition must allow general anesthesia

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- See Disease Characteristics

- No prior bone marrow transplantation

- More than 4 weeks since other prior biologic therapy and recovered

Chemotherapy:

- See Disease Characteristics

- More than 4 weeks since prior chemotherapy (at least 6 weeks for nitrosoureas or
mitomycin) and recovered

Endocrine therapy:

- Not specified

Radiotherapy:

- More than 4 weeks since prior radiotherapy and recovered

Surgery:

- Not specified